These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
115 related articles for article (PubMed ID: 26389154)
21. [Bevacizumab in the treatment of colorectal carcinoma: news from ASCO 2008]. Mansueto G; Longo F Tumori; 2008; 94(4):suppl 1-14. PubMed ID: 18822711 [No Abstract] [Full Text] [Related]
22. Chemotherapy and resection for colorectal metastases. Fong Y Lancet Oncol; 2013 Nov; 14(12):1148-9. PubMed ID: 24120479 [No Abstract] [Full Text] [Related]
26. [Capecitabine and irinotecan]. Gasperoni S Suppl Tumori; 2004; 3(4):S107-8. PubMed ID: 15206231 [No Abstract] [Full Text] [Related]
27. [Hepatic arterial infusion chemotherapy for liver metastases from colorectal cancer]. Arai Y; Matsueda K; Inaba Y Gan To Kagaku Ryoho; 2000 Dec; 27(14):2193-200. PubMed ID: 11142162 [TBL] [Abstract][Full Text] [Related]
28. [Adjuvant therapy of colon carcinoma: results of two Intergroup Studies (INT-0035 and INT-0089), a study by the German Cancer Aid 17-1A Study Group and the IMPACT Study]. Petrasch S; Schmiegel W Z Gastroenterol; 1997 Jan; 35(1):49-52. PubMed ID: 9123959 [No Abstract] [Full Text] [Related]
29. Strategic options on behalf of patients with metastatic colorectal cancer: mass tumor murder versus serial tumor killing. Goldberg RM Onkologie; 2010; 33(6):291-2. PubMed ID: 20523091 [No Abstract] [Full Text] [Related]
30. Methodologic diligence is needed to define and validate tumor-size response metrics to predict overall survival in first-line metastatic colorectal cancer. Mansmann UR; Laubender RP J Clin Oncol; 2013 Dec; 31(34):4373-4. PubMed ID: 24166531 [No Abstract] [Full Text] [Related]
31. Registries and randomized trials in assessing the effects of bevacizumab in colorectal cancer: is there a common theme? Hurwitz HI; Lyman GH J Clin Oncol; 2012 Feb; 30(6):580-1. PubMed ID: 22253468 [No Abstract] [Full Text] [Related]
32. Short time infusion of bevacizumab in combination with 5FU-based chemotherapy as first-line therapy in a non-selective patient group with metastatic colorectal cancer. Dohn LH; Jensen BV; Larsen FO Acta Oncol; 2010 Apr; 49(3):395-6. PubMed ID: 20001495 [No Abstract] [Full Text] [Related]
33. Is there a difference in demography and clinical characteristics in patients treated with and without bevacizumab? Hartmann H; Müller J; Marschner N J Clin Oncol; 2012 Sep; 30(26):3317-8; author reply 3318. PubMed ID: 22649139 [No Abstract] [Full Text] [Related]
34. Current treatment benefits in advanced colorectal cancer. Scheithauer W Lancet Oncol; 2007 Oct; 8(10):857-9. PubMed ID: 17913652 [No Abstract] [Full Text] [Related]
35. Response phenotype as a predictive biomarker to guide treatment with targeted therapies. Oxnard GR; Schwartz LH J Clin Oncol; 2013 Oct; 31(30):3739-41. PubMed ID: 24043750 [No Abstract] [Full Text] [Related]